Nauck, M
For chronic weight management, the FDA has approved specific formulationsWegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide)for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Tennoune, N
So we are specifically interested in the effect of aging in conjunction with GLP-1 medicines and what that does to skin and muscle because there is this point in life where having a low body weight and a lower BMI epidemiologically very well proven is actually detrimental to life expectancy and quality of life in these things
Even with increased coverage for Wegovy in 2025, 83% of people with coverage still face restrictions like prior authorization or step therapy, whether theyre prescribed the medication for obesity, cardiovascular disease, or any other indication
Starting July 2026, a short-term program called the Medicare GLP-1 Bridge, designed as a bridge to the broader BALANCE model, will cover Wegovy, Zepbound and Foundayo for eligible Part D enrollees at a $50 monthly copayment
